Gallbladder & bile duct Carcinoma Dr. m. h.khosravi

download Gallbladder & bile duct Carcinoma Dr. m. h.khosravi

of 22

  • date post

  • Category


  • view

  • download


Embed Size (px)

Transcript of Gallbladder & bile duct Carcinoma Dr. m. h.khosravi

  • Gallbladder & bile duct CarcinomaDr. m. h.khosravi

  • Carcinoma of the Gall bladder Incidence 2 4 % of all GI tumor F/M : 2-3 / 1 0/4 % in random autopsy 1% incidentally in cholecystectomy

  • Etiology

    90% have gall stones Polypoid lesions, particulary larger than 10 mmPorcelain gallbladderCholedochal cysts

  • Pathology

    Adenocarcinomas is 80-90%histologic subtypes are papillary, nodular, and tubular.Cancer spreads through the lymphatics, venous drainage, and with direct invasion

  • Clinical Manifestations

    abdominal discomfort, right upper quadrant pain, nausea, and vomiting.less common: Jaundice, weight loss, anorexia, ascites, and abdominal mass

  • Diagnosis

    UltrasonographyCT scanERCPTCMRCP

  • Treatment

    Surgery is the only curative optionTumors limited to the muscular layer (T1) need simple cholecystectomy

  • tumor invades the perimuscular connective tissue without extension beyond the serosa or into the liver (T2 tumors)need extended cholecystectomyThat includes resection of liver segments IVB and V, and lymphadenectomy of the cystic duct, and pericholedochal,portal, right celiac, and posterior pancreatoduodenal lymph node

  • tumors that grow beyond the serosa or invade the liver or other organs (T3 and T4 tumors),need extended right hepatectomy (segments IV, V,VI, VII, and VIII)

  • Prognosis

    5-year survival rate of all patients is less 5%median survival is 6 months.median survival in distant metastasis is only 1 to 3 months.

  • Bile Duct Carcinoma

    Incidence autopsy incidence is about 0.3% overall incidence of is about 1.0 per 100,000 people per year M/F : 1.3 /1

  • Etiology

    Primary sclerosing cholangitis choledochal cysts ulcerative colitis hepatolithiasis biliary-enteric anastomosis infection with Clonorchis or in chronic typhoid carriers.

  • Pathology

    Adenocarcinomas is Over 95%Anatomically divided into distal, proximal, or perihilar tumors.Bismuth-Corlette classification

  • Clinical Manifestations

    Painless jaundicePruritus,mild right upper quadrant pain,anorexia,fatigue,weight loss

  • Diagnosis

    ultrasoundCT scanCholangiography( PTC, ERC )celiac angiographyMRI

  • Treatment

    Surgical excision is the only potentially curative treatmentunresectable perihilar cholangiocarcinoma need Roux-en- Y cholangiojejunostomy to segment II or III bile ducts or to the right hepatic duct

  • Perihilar tumors involving the bifurcation or proximal common hepatic duct (Bismuth-Corlette type I or II) need local tumor excision with portal lymphadenectomy cholecystectomy, common bile duct excision, and bilateral Roux-en- Y hepaticojejunostomies.

  • tumor involves the right or left hepatic duct (Bismuth-Corlette type lIIa or lIIb)need right or left hepatic lobectomy,Distal resectable tumor need pancreatoduodenectomy (Whipple procedure).

  • Distal unresectable tumor need Roux-en- Y hepaticojejunostomy,cholecystectomy, and gastrojejunostomyunresectable tumor on diagnostic evaluation need stent

  • Prognosis

    median survival in Patients with unresectable tumor is between 5 and 8 months.5-year survival rate in resectable perihilar tumor is 10 and 30%.operative mortality is 6-8% .